Novavax Inc
NASDAQ:NVAX

Watchlist Manager
Novavax Inc Logo
Novavax Inc
NASDAQ:NVAX
Watchlist
Price: 6.78 USD -1.88% Market Closed
Market Cap: 1.1B USD

Novavax Inc
Tax Provision

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Novavax Inc
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Novavax Inc
NASDAQ:NVAX
Tax Provision
-$8.9m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Tax Provision
$735m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Tax Provision
-$1.8B
CAGR 3-Years
-13%
CAGR 5-Years
-28%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Tax Provision
-$1.2B
CAGR 3-Years
-11%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Tax Provision
-$773.6m
CAGR 3-Years
-1%
CAGR 5-Years
-29%
CAGR 10-Years
-37%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Tax Provision
-$567.1m
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
1%
No Stocks Found

Novavax Inc
Glance View

Nestled at the intersection of innovation and dedication, Novavax Inc. emerged as a pivotal player in the biopharmaceutical landscape. Founded in 1987, the company was initially envisioned to be a biotechnology firm focused on life-saving vaccines, a mission that would increasingly align with global needs. Through diligent research and development, Novavax adopted a recombinant nanoparticle technology platform, enabling the company to develop distinctive vaccines. Using proprietary adjuvants to bolster immune responses, their work is characterized by precision and high efficacy. Novavax’s journey gained substantial momentum during the COVID-19 pandemic, as the urgent demand for vaccines spotlighted their potential. The development of their COVID-19 vaccine candidate, leveraging this cutting-edge technology, became a critical milestone, underscoring their adaptability and competence in addressing modern health challenges. From a business perspective, Novavax crafts its success by guiding innovative vaccine candidates through rigorous stages of clinical trials and regulatory approvals, ultimately leading to revenue generation via licensing agreements and government contracts. They meticulously balance risk and opportunity by targeting a spectrum of infectious diseases, aiming to broaden their product pipeline and thus capture larger market shares. Revenue flows primarily from the sale of these vaccines, which are distributed worldwide, and the company continues to explore partnerships and collaborations to enhance its market reach. Novavax showcases resilience and forward-thinking strategies, underpinned by a commitment to expanding access to essential vaccines globally, thereby meeting both public health needs and corporate growth objectives.

NVAX Intrinsic Value
5.67 USD
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Novavax Inc's Tax Provision?
Tax Provision
-8.9m USD

Based on the financial report for Sep 30, 2025, Novavax Inc's Tax Provision amounts to -8.9m USD.

What is Novavax Inc's Tax Provision growth rate?
Tax Provision CAGR 3Y
27%

Over the last year, the Tax Provision growth was -74%. The average annual Tax Provision growth rates for Novavax Inc have been 27% over the past three years .

Back to Top